Jorge Alonso-Pérez1, Sonia Segovia2, Cristina Domínguez-González3, Montse Olivé4, María Dolores Mendoza Grimón5, Roberto Fernández-Torrón6, Adolfo López de Munain6, José Luis Muñoz-Blanco7, Alba Ramos-Fransi8, Miriam Almendrote8, Isabel Illa9, Jordi Díaz-Manera10. 1. Unidad de Patología Neuromuscular, Departamento de Neurología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España. 2. Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER). 3. Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER); Unidad de Neuromuscular, Servicio de Neurología, Hospital Universitario 12 de Octubre, Instituto de investigación i+12, Madrid, España. 4. Servicio de Anatomía Patológica (Neuropatología) y Unidad de Patología Neuromuscular, Hospital Universitari de Bellvitge, Barcelona, España. 5. Servicio de Neurología, Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, España. 6. Servicio de Neurología, Hospital de Donosti, San Sebastián, España. 7. Servicio de Neurología, Hospital Gregorio Marañón, Madrid, España. 8. Servicio de Neurología, Hospital Germans Trias i Pujol, Badalona, España. 9. Unidad de Patología Neuromuscular, Departamento de Neurología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España; Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER). 10. Unidad de Patología Neuromuscular, Departamento de Neurología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España; Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER). Electronic address: jdiazm@santpau.cat.
Abstract
INTRODUCTION AND OBJECTIVES: Pompe disease is a rare autosomal recessive disorder produced by a deficiency of acid maltase. This deficit produces an accumulation of glycogen in tissues. Clinically it is mainly characterized by limb girdle and respiratory muscle weakness. In 2013, we developed the Spanish Pompe Registry. The objective of this article was to analyse the characteristics of the first 49 patients and disclose the existence of this registry within the medical community. MATERIAL AND METHODS: An observational retrospective study was undertaken. We analysed the 49 patients included in the Spanish Registry of Pompe Disease from May 2013 to October 2018. RESULTS: Patients were visited at 7 different Spanish hospitals. Twenty-six patients were women and 23 were men. The average age at the time of the analysis was 47.2 years. Ten patients were asymptomatic. The mean age of onset of symptoms was 29, and low limb girdle weakness was the most frequent initial symptom. Of the patients, 49% had respiratory involvement, and 70.8% of them required non-invasive mechanical ventilation. The most common mutation found was IVS1-13T>G in 85.3% of the patients. All symptomatic patients received treatment with ERT. CONCLUSIONS: This registry allows us to know the clinical and genetic characteristics of adult patients with Pompe disease in Spain. Moreover, it can be the basis for future studies of natural history to understand the impact of ERT in the course of the disease.
INTRODUCTION AND OBJECTIVES: Pompe disease is a rare autosomal recessive disorder produced by a deficiency of acid maltase. This deficit produces an accumulation of glycogen in tissues. Clinically it is mainly characterized by limb girdle and respiratory muscle weakness. In 2013, we developed the Spanish Pompe Registry. The objective of this article was to analyse the characteristics of the first 49 patients and disclose the existence of this registry within the medical community. MATERIAL AND METHODS: An observational retrospective study was undertaken. We analysed the 49 patients included in the Spanish Registry of Pompe Disease from May 2013 to October 2018. RESULTS:Patients were visited at 7 different Spanish hospitals. Twenty-six patients were women and 23 were men. The average age at the time of the analysis was 47.2 years. Ten patients were asymptomatic. The mean age of onset of symptoms was 29, and low limb girdle weakness was the most frequent initial symptom. Of the patients, 49% had respiratory involvement, and 70.8% of them required non-invasive mechanical ventilation. The most common mutation found was IVS1-13T>G in 85.3% of the patients. All symptomatic patients received treatment with ERT. CONCLUSIONS: This registry allows us to know the clinical and genetic characteristics of adult patients with Pompe disease in Spain. Moreover, it can be the basis for future studies of natural history to understand the impact of ERT in the course of the disease.
Keywords:
Enfermedad de Pompe; Enzyme replacement therapy; Glucogenosis tipo II; Glycogenosis type II; Patient registry; Pompe disease; Registro Español de Enfermedades Neuromusculares; Registro de pacientes; Spanish Registry of Neuromuscular Diseases; Terapia enzimática sustitutiva
Authors: Paula Hernández-Arévalo; José D Santotoribio; Rocío Delarosa-Rodríguez; Antonio González-Meneses; Salvador García-Morillo; Pilar Jiménez-Arriscado; Juan M Guerrero; Hada C Macher Journal: Orphanet J Rare Dis Date: 2021-05-21 Impact factor: 4.123
Authors: Araceli Aguilar-González; Juan Elías González-Correa; Eliana Barriocanal-Casado; Iris Ramos-Hernández; Miguel A Lerma-Juárez; Sara Greco; Juan José Rodríguez-Sevilla; Francisco Javier Molina-Estévez; Valle Montalvo-Romeral; Giuseppe Ronzitti; Rosario María Sánchez-Martín; Francisco Martín; Pilar Muñoz Journal: Int J Mol Sci Date: 2022-06-04 Impact factor: 6.208
Authors: Mai K ElMallah; Ankit K Desai; Erica B Nading; Stephanie DeArmey; Richard M Kravitz; Priya S Kishnani Journal: Pediatr Pulmonol Date: 2020-01-03